Clinical Performance of da Vinci 5 Versus Xi for Robotic Anatomic Lung Resection: A Propensity-Weighted Analysis
This propensity-weighted analysis demonstrates that the da Vinci 5 robotic system offers comparable safety and oncologic quality to the Xi platform for anatomic lung resection, while significantly reducing operative time and showing trends toward fewer complications and shorter hospital stays.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
For decades, the standard way to remove a lung tumor has been to make a large incision between the ribs, a procedure that is effective but often leaves patients with significant pain and a long recovery. Over time, surgeons have shifted toward minimally invasive techniques, using small cuts and cameras to perform the same operation with less trauma to the body. Among these methods, robotic surgery has emerged as a powerful tool. In this approach, a surgeon sits at a console and controls robotic arms that hold tiny instruments inside the patient's chest. These arms offer a level of precision and flexibility that human hands cannot match, allowing for delicate work around the heart and major blood vessels. The technology has evolved through several generations, with the most recent version, the da Vinci 5, introducing a new feature called force feedback. This capability allows the surgeon to feel the resistance of the tissue they are touching, much like a hand feeling the texture of an object, a sensation that previous robotic systems could not provide.
The question facing the medical community was whether this newest generation of robotic technology actually improves the outcome of lung surgery compared to the established system it replaced. A team of researchers at NYU Langone Health set out to answer this by comparing lung resections performed with the older da Vinci Xi system against those done with the new da Vinci 5. They focused on patients with early-stage lung cancer who needed a portion of their lung removed, a procedure known as anatomic lung resection. The goal was to see if the new machine could match the safety and cancer-fighting quality of the old one while potentially making the surgery faster or easier.
To ensure a fair comparison, the researchers looked at 294 patients who underwent this surgery between January 2025 and August 2026. Because the patients in the two groups were not identical at the start—some had larger tumors or different health conditions—the team used a statistical method to balance the groups, effectively creating a scenario where the only major difference was the robotic system used. This allowed them to isolate the effect of the technology itself. The study found that the new da Vinci 5 system was just as safe as the older Xi system. There were no deaths within 30 or 90 days of the surgery in either group, and no patient needed to be converted to a large, open chest incision. The cancer was removed completely in every single case, and the number of lymph nodes collected for examination was nearly identical between the two groups, ensuring that the quality of the cancer treatment was not compromised.
The most notable difference emerged in how long the surgeries took. Patients operated on with the da Vinci 5 had their procedures completed in an average of 96.4 minutes, while those with the older Xi system took an average of 118.7 minutes. This reduction of roughly 22 minutes suggests that the new platform offers a measurable efficiency advantage. The researchers also observed that patients using the new system tended to have slightly less blood loss and a shorter hospital stay, though these differences were smaller and less definitive. One interesting observation involved the management of chest tubes, which are drains placed after surgery to remove fluid and air. A specific surgeon in the study, who performed the majority of the operations, was more likely to leave the operating room without placing a chest tube when using the da Vinci 5 compared to the Xi system. While this practice is not standard for all surgeons, it hints that the new system's ability to provide a better sense of tissue handling might give surgeons more confidence that the lung is sealed tightly enough to heal without a drain.
The study does not claim that the new system is a miracle cure or that it is perfect for every situation. The researchers were careful to note that the reduction in surgery time could be influenced by the surgeons becoming more experienced with the new machine over time, rather than the machine itself being inherently faster. They also pointed out that they could not measure exactly how the force feedback feature was used during the operations, so they cannot say for certain that this specific feature caused the improvements. However, the findings provide strong early evidence that the da Vinci 5 system preserves the high safety and cancer-treatment standards of its predecessor while potentially streamlining the surgical process. As hospitals begin to adopt this fifth-generation technology, these results suggest that patients can expect the same high-quality care with the possibility of a more efficient operation, though larger studies will be needed to confirm these benefits across different hospitals and surgeons.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.